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Abstract
Background: Despite their huge epidemiological impact, primary headaches, trigeminal neuralgia and other chronic
pain conditions still receive suboptimal medical approach, even in developed countries. The limited efficacy of current
pain-killers and prophylactic treatments stands among the main reasons for this phenomenon. Botulinum neurotoxin
(BoNT) represents a well-established and licensed treatment for chronic migraine, but also an emerging treatment for
other types of primary headache, trigeminal neuralgia, neuropathic pain, and an increasing number of pain conditions.
Methods: We searched and critically reviewed evidence for the efficacy of BoNT for the treatment of chronic pain.
Results: Meta-analyses and randomized controlled trials (RCTs) suggest that BoNT potentially represents a multi-purpose
drug for the treatment of pain in several disorders due to a favorable safety profile and a long-lasting relief after a single
injection.
Conclusions: BoNT is an emerging treatment in different pain conditions. Future RCTs should explore the use of BoNT
injection therapy combined with systemic drugs and/or physical therapies as new pain treatment strategies.
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Introduction
The prevalence of moderate-to-severe chronic non-cancer
pain in Europe is estimated to be 20% [1]. A large
population-based study on the prevalence of primary
headache (PH) disorders in Germany estimated that 2.6%
of the general population suffer from headache ≥15 days/
month, and 1.1% from chronic migraine [2]. Medication-
overuse headache (MOH), i.e., chronic headache resulting
from excessive consumption of pain-killers for headache,
has an estimated worldwide prevalence of 0.5–7.2% [3].
Around 7% in the general population suffer from some
form of chronic neuropathic pain (NP) [4].
The social and economic burden of chronic pain is
staggering, in that it interferes with everyday activities,
lowers productivity, affects personal relationships, and
results in depressive symptoms. WHO ranks migraine as
the sixth highest cause of disability worldwide when
considered alone, and the third highest when MOH is
included [5]. According to U.S. figures, the total annual
median cost for medical services and analgesics for the
relief of migraine, low back pain, and fibromyalgia is
roughly $5,000 and more than $25,000 for treating HIV-
related pain and multiple sclerosis [6]. Though lower
than the estimated $50,000 spent for ameliorating cancer
pain [6], the toll that persistent pain and PH take on
overall wellbeing is heavier because of the chronic
course of the underlying condition.
Most patients with PH and chronic pain do not receive
satisfactory treatment. A European survey reported that
43–81% of patients with headache were not satisfied with
their treatment, and the main reason was poor effective-
ness of prescribed drugs [7]. Around 25–50% of patients
with trigeminal neuralgia (TN) become refractory to drug
therapy, and surgical procedures are not always feasible in
these patients, and they may occasionally result in severe
complications [8]. Only 30–40% of patients with NP
achieve a ≥50% pain reduction with currently available
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therapies [9]. In a recent meta-analysis that took into
account publication bias for negative studies, the Special
Interest Group on Neuropathic Pain (NeuPSIG) of the
International Association for the Study of Pain found that
the number-needed-to-treat (NNT) for first-line NP drugs
is 3.6–7.7, indicating that less than 30% of patients are
responders, and the figures for other treatments are
even worse [10]. The number-needed-to-harm (NNH)
for these drugs ranges from 11.8 to 31.9, resulting in
high drop-out rates [10]. Non-opioid analgesics, non-
steroidal anti-inflammatory drugs, cyclooxygenase-2
inhibitors, and opioids are widely used for relieving
nociceptive pain; however, following increased reports
of adverse events and side effects, recent warnings
and guidelines have been issued, advising caution
when prescribing them [11]. Because current pharma-
cological approaches to PH, TN, NP and other types
of chronic pain are inadequate and subject to unin-
tentional abuse, alternative treatment options need to
be reconsidered.
Botulinum neurotoxin (BoNT), a potent natural
toxin produced by the anaerobic bacterium Clostri-
dium botulinum, blocks the release of acetylcholine at
the neuromuscular junction by inhibiting the soluble
N-ethylmaleimide-sensitive factor attachment protein
receptor (SNARE) complex. Since the use of BoNT
for the treatment of strabismus was pioneered more
than 40 years ago, the therapeutic indications for
BoNT type A (BoNT-A) and, more recently, type B
for treating excessive and/or undesired muscle tone, have
progressively expanded [12]. Currently available BoNT
formulations, i.e., abobotulinumtoxin-A (Dysport;
Ipsen, Paris, France), incobotulinumtoxin-A (Xeomin,
Merz Pharmaceuticals GmbH, Frankfurt, Germany),
onabotulinumtoxin-A (Botox; Allergan, Inc., Irvine, CA,
USA), and rimabotulinumtoxin-B (Myobloc/Neurobloc;
Solstice Neurosciences, Inc., San Francisco, CA, USA) are
licensed for the treatment of spasticity and dystonia, and
were applied in 17 million treatments between 1994 and
2013 in the United States alone [12]. Though the formula-
tions differ in pharmacological profile, potency, dosage,
and approved indications, BoNT is recognized as a safe
and effective treatment for spasticity resulting from stroke,
multiple sclerosis and spinal cord injury, as well as for
dystonia, tremor, and other movement disorders [12].
Guidelines and expert opinions derived from broad-
based, high-quality evidence recommend the use of
BoNT either alone or in combination with rehabilita-
tion procedures as first-line treatment for spasticity
and focal dystonia [13–15].
Not surprisingly, BoNT was found to reduce pain in
spasticity, dystonia, and related conditions where pain re-
duction is an important outcome [13, 14]. Serendipitous
clinical observations that pain symptoms may improve
independently of muscle hyperactivity and with a different
time course after BoNT injection have spurred the explor-
ation of the mechanisms underlying this effect in animal
models and the collection of evidence in clinical settings
[16]. Animal models indicate that BoNT may be effective
in controlling pain via its interaction with the SNARE
complex that blocks synaptic vesicle fusion and inhibits
the release of various pain-modulating neurotransmitters,
including glutamate, substance P, calcitonin gene-related
peptide, and pain-sensing transmembrane receptors, such
as transient receptor potential channels on the neuronal
plasma membrane [16]. In addition, growing evidence
suggests that the analgesic and anti-inflammatory effects
of BoNT are mediated through various molecular path-
ways in both the peripheral nerves and the spinal cord
[16]. Figure 1 summarizes the neurobiological mecha-
nisms through which BoNT may modulate pain, and their
possible anatomical levels.
Here we reviewed published evidence on the use of
BoNT for the treatment of pain. Since a number of
meta-analyses have already been published on this topic,
we chose a narrative approach, focusing more specifi-
cally on a critical review of current data and possible
future approaches.
Methods
The electronic database MEDLINE (accessed by Pubmed;
1 January 2006–31 December 2016) was searched with
the string ((“pain” [MeSH Terms] OR “pain” [All Fields])
AND (“botulinum toxins” [MeSH Terms] OR (“botulinum”
[All Fields] AND “toxins” [All Fields]) OR “botulinum
toxins” [All Fields] OR (“botulinum” [All Fields] AND
“toxin” [All Fields]) OR “botulinum toxin” [All Fields]))
AND (Clinical Trial[ptyp] OR (“meta-analysis” [Publica-
tion Type] OR “meta-analysis as topic” [MeSH Terms] OR
“meta-analysis” [All Fields])) with no language restrictions
and all the titles and abstracts identified by the search
were evaluated for eligibility.
Results
The PubMed searched yielded 84 randomized controlled
trials (RCTs) and 36 meta-analyses or systematic reviews,
indicating a consistent bulk of data on the role of BoNT-A
for the treatment of chronic pain. The conditions for
which at least one meta-analysis was available are summa-
rized in Table 1.
Based on the PREEMPT program that included data
from two multicenter RCTs (n = 1384 patients), BoNT-A
was given regulatory approval for the treatment of
chronic migraine (CM) in 2010, the fact notwithstanding
that its mechanism of action is not yet completely
elucidated [17]. A meta-analysis on the role of BoNT as
a prophylactic treatment of migraine showed that
BoNT-A compared with placebo was associated with a
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small-to-modest benefit for chronic daily headache and
CM (i.e., a mean −2.1 to −2.3 reduction in headache
episodes per months), but was not associated with fewer
episodic migraine or chronic tension-type headaches
(TTHs) per month [18]. A RCT on the treatment of MOH
failed to document an effect on the headache days, but
showed a reduction of drug consumption [19]. Overall,
BoNT adverse events were few and not serious in CM pa-
tients [20].
Open-label data suggest that intramuscular injection of
BoNT-A in the masseter muscle may improve pain in pa-
tients with temporomandibular disorders (TMD) and
TTH [21]. Systematic reviews on TMD reported signifi-
cant myofascial pain reduction following BoNT treatment
in comparison to placebo in two RCTs, no significant
difference in two RCTs, and equal efficacy of BoNT and
fascial manipulation in one RCT, but a meta-analysis was
not possible because of considerable variations in study
design and outcomes [22].
Five high quality RCTs indicated little or no effect of
BoNT-A, and two very low quality RCTs suggested little
or no difference between BoNT-A and placebo, both
combined with physiotherapeutic exercise and analgesics,
in patients with chronic neck pain [23]. A very low quality
RCT showed little or no effect of BoNT-A in chronic
cervicogenic headache [23]. Three RCTs showed no effect
of BoNT-A in pain related to whiplash injury [24].
A recently published meta-analysis concluded that
BoNT-A may be an effective and safe treatment option
for patients with TN, in that it yielded, on average, a
Fig. 1 The neurobiological mechanisms of the effect of botulinum neurotoxin (BonT) on pain according to animal models [16] and the anatomical
levels where they may take place. Panel a shows a normal axon and the role of the soluble N-ethylmaleimide-sensitive factor attachment protein
receptor (SNARE) complex, here represented by a chain, for allowing the fusion between the synaptic vescicles (red circles) containing a
neurotransmitter (black dots) and the axonal membrane resulting in the neurotransmitter release. Panel b shows the effect of the BoNT,
represented by scissors that cleave the SNARE complex and impede vescicle fusion and neurotransmitter release. Panel c shows peripheral
sensitization after tissue injury, which results in the release of a number of inflammatory mediators (e.g., histamine, bradykinin, prostaglandins,
interleukins, adenosine, and nerve growth factors) that, in turn, induce the expression of transient receptor potential (TRP) channels and cause
sensitization of the peripheral nociceptor. BoNT may cleave the SNARE complex, block fusion of the vescicles (blue circles) containing TRP channels
(white dots) and reduce peripheral nociceptor sensitization. This mechanism may contribute to the effect of BoNT on nociceptive pain and peripheral
neuropathic pain (NP). Panel d shows retrograde axonal transport of BoNT to the dorsal horn of the spinal cord where it can block the release of
pain-modulating neurotransmitters, such as glutamate, substance P, and calcitonin gene-related peptide (CGRP). This mechanism may reduce central
sensitization phenomena and spinal NP
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−29.8 reduction in paroxysms per day [8]. Conversely,
BoNT was not found to be effective in occipital neur-
algia [25].
RCTs have documented that BoNT-A may be effective
in peripheral NP, including painful diabetic neuropathy,
post-herpetic and post-traumatic neuralgia [26]. A
meta-analysis including two studies on diabetic NP
showed a −2.0 reduction on a 0–10 visual analogue
scale (VAS) following treatment with BoNT-A, resulting
in clinically significant improvement of minimum change
in pain, with no more adverse effects than placebo [27]. A
RCT on peripheral NP documented a −0.8 reduction in
numerical rating scale over 24 weeks compared with
placebo [26]. A RCT on NP secondary to spinal cord
injury showed significant reduction at 4 weeks (active:
18.6 ± 16.8; placebo: 2.6 ± 14.6) and 8 weeks (active: 21.3
± 26.8; placebo: 0.3 ± 19.5) after BoNT-A [28]. The NeuP-
SIG recommended BoNT-A as third line pharmacological
treatment for NP, assigning it the same strength of recom-
mendation as strong opioids [10]. This recommendation
was largely based on the high tolerability of BoNT-A and
the safety concerns related to opioids, despite the fact that
effectiveness and the bulk of evidence favoring opioids,
particularly oxycodone and morphine, is far more robust
[10].
Eight RCTs documented no significant effect of
BoNT-A in myofascial pain syndrome [24].
Studies with a small sample size and a high risk of bias
have suggested that intramuscular BoNT-A injection
may reduce pain (i.e., on average between −1.2 and −2.0
Table 1 Evidence for the use of BoNT-A in chronic pain conditions
Condition Subjects Studies Comparator Outcomea Ref.
EM 1838 9 Placebo n.s. 18
CM 1508 5 Placebo HEPM: −2.30 [95% CI: −3.7, −0.9] 18
59 1 Topiramate n.s. 18
72 1 Amitriptyline n.s. 18
CDH 1115 1 Placebo HEPM: −2.1 [95% CI: −3.6, −0.6] 18
Any TTH 59 1 Valproate n.s. 18
21 1 Steroids HEPM: −2.5 [95% CI:−3.5, −1.5] 18
Chronic TTH 675 7 Placebo n.s. 18
TMD 145 4 Placebo Meta-analysis not performed 22
30 1 Manipulation n.s. 22
CNPb 371 8 Placebo Little or no difference 23
CCH 32 1 Placebo Little or no difference 23
Whiplash 96 3 Placebo n.s. 24
TN 178 4 Placebo PPD: −29.8 [95% CI:−38.5, −21.1] 8
Diabetic NP 76 2 Placebo 0–10 VAS: −2.0 [95% CI:−3.1, −0.8] 27
Peripheral NP 68 1 Placebo 0–10 NRS:-0.8 [95% CI:−1.0, −0.6] 26
Spinal NP 40 1 Placebo Significant VAS reduction 28
Myofascial 332 8 Placebo n.s. 24
PSSP 86 5 Placebo 0–10 VAS: −1.2 [95% CI:−2.4, −0.1] 29
ASP 40 1 Placebo 0–10 VAS −2.0 [95% CI:−3.7, −0.3] 29
LE 274 4 Placebo ES: −0.5 [95% CI:−0.9, −0.1] 31
LBP 131 3 Mixedc Meta-analysis not performed 33
Ankle OA 75 1 HA n.s. 34
PF 133 3 Placebo n.s. 35
136 2 Steroids Pain relief: −0.7 [95% CI:−1.0, −0.3] 35
BPS 317 6 Placebo 0–10 VAS −1.7 [95% CI:−3.2, −0.3] 38
Here are reported chronic pain conditions for which at least one meta-analysis or systematic review was available. ASP Arthritic shoulder pain, BoNT-A Botulinum
neurotoxin type A, BPS Bladder pain syndrome, CCH Chronic cervicogenic headache, CDH Chronic daily headache, CI Confidence interval, CM Chronic migraine,
CNP Chronic neck pain, EM Episodic migraine, ES Effect size, HA Hyaluronic acid, HEPM Headache episodes per months, LBP Low back pain, LE Lateral epycondylitis,
NP Neuropathic pain, NRS Numerical rating scale, n.s. Not significant, OA Osteoarthritis, PF Plantar fasciitis, PPD Paroxysms per day, PSSP Post-stroke shoulder pain,
TMD Temporomandibular disorders, TN Trigeminal neuralgia, TTH Tension type headache, VAS Visual analogue scale
aResults of the comparison between BoNT and comparator
bPhysiotherapeutic exercise and analgesics were combined with both BoNT and placebo in two studies (n = 95 patients)
cPlacebo, acupuncture or steroids
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points on a 0–10 VAS) and improve function in chronic
shoulder pain from spastic hemiplegia or arthritis [29].
A similar effect was documented after intra-articular
BoNT-A injection for refractory hemiplegic shoulder
pain [30].
Four RCTs documented a moderate effect on pain to
BoNT-A 60 U injection into the forearm extensor muscles
in chronic treatment-resistant lateral epicondylitis [31]. A
recent Bayesian network meta-analysis that compared
different injection therapies for lateral epicondylitis
showed a not significant trend towards better effect than
placebo for BoNT-A [32].
Three RCTs showed that BoNT-A improves pain, func-
tion, or both better than saline injections, acupuncture or
steroid injections in patients with low back pain and sciat-
ica, but the low-quality and heterogeneity of studies im-
peded a meta-analysis [33].
A RCT on ankle osteoarthritis reported no significant
difference between BoNT and hyaluronic acid, which in
turn appeared not more effective than exercise therapy,
and did not seem to offer clinically relevant advantage in
comparison to placebo [34]. Data from three RCTs
documented no significant difference between BoNT-A
and placebo, and those from two RCTs showed slight
significant advantage of BoNT-A over corticosteroids in
plantar fasciitis, but a network meta-analysys including
22 RCTs indicated BoNT-A as the most likely treatment
to relieve pain in this condition [35].
Limited evidence of efficacy for peripheral BoNT
injection therapy for residual limb pain after amputation
is suggested by very small trials and case series, while a
small RCT showed that BoNT-A was not superior to
lidocaine and methylprednisolone in this condition [36].
Pelvic pain, also known as bladder pain syndrome
(BPS) or interstitial cystitis, is a complex condition with
an ill-defined pathogenesis [37]. Six RCTs showed that
intravesical BoNT-A injections might offer significant
improvement in pain (i.e., average −1.7 points reduction
on a 0–10 VAS), daytime urination frequency, and max-
imum cystometric capacity for patients with refractory
BPS [38].
BoNT-A was found to improve post-surgical and post-
radiation pain in cancer patients in a small open-label
study [39].
Discussion and conclusions
The current evidence reviewed here indicate that BoNT-A
represents an effective prophylactic treatment for CM,
and may be helpful in other types of cranial, facial, and
cervical pain, as well as in patients with TN, peripheral
and spinal NP, some types of pain secondary to musculo-
skeletal diseases, and BPS. For most of these conditions,
however, the quality of evidence is low, and the sample
size of RCTs is small. In some conditions, such as NP,
where the evidence for first-line treatments (i.e., α2-δ
ligands, antidepressants) comes from a consistently larger
number of patients, evidence supporting the use of BoNT
should be considered with caution and preliminary.
Neurobiological grounds for the use of BoNT in pain
come from experimental models [16]. Despite the
heterogeneity of conditions, routes of administration,
and outcomes, studies that sought to identify best-
responder profiles suggest that complete denervation or
nerve transection predicts poor pain response to BoNT
[26, 28]. This clinical observation is in keeping with
animal models that indicate that the analgesic effect of
BoNT is mediated, at least in part, by retrograde axonal
transport to the spinal cord [16].
According to the International Classification of Headache
Disorders, the essential diagnostic criteria of PH disorders
are based on the presence of specific clinical features and
the absence of decisive pathological or radiological findings.
It is noteworthy that the classification of a patient in a given
PH subtype may change in a quarter of cases, especially
when the diagnosis is probable, even in expert centers [40].
Patients suffering from chronic migraine frequently report
other types of pain (i.e., fibromyalgia), and both types of
pain are usually more or less refractory to common
treatments [41].
Identifying different types of pain (e.g., neuropathic,
osteoarticular, or associated with excessive muscle tone)
in the same patient represents the first step towards
developing a more appropriate and mechanisms-based
pharmacological prescription for pain [11]. Guidelines
and diagnostic algorithms for the management of NP
may be difficult to apply in clinical conditions such as
low back pain, for example, where different types of pain
coexist [42]. While stratification of NP patients by their
underlying sensory profile has been suggested to better
inform the design of RCTs and personalized pharmaco-
logical treatment, the clinical utility of this tempting
approach has not yielded more favorable NNT-NNH
profiles for NP drugs [9]. Clinical scenarios are more
complex and ‘real-world’ patients are very different from
those enrolled in RCTs. Diagnosis of NP according to
the NeuPSIG diagnostic algorithm has many merits,
including different levels of certainty (i.e., probable,
possible, definite), but it requires a solid knowledge of
central and peripheral nervous system anatomy that not
all pain physicians may possess [42]. The elderly and
neurological patients may have several comorbidities
and cognitive impairments that can blur the clinical
expression of pain. Furthermore, thorough examination
to evaluate the different types of pain may not be pos-
sible due to time constrictions in some cases.
BoNT-A was found to be effective for relieving PH,
TN, NP, nociceptive and osteoarticular pain, as well as
pain symptoms associated with muscle hypertonus. Its
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effect on different pain mechanisms coexisting in the
same patient, together with its favorable side effect pro-
file and long-lasting pain relief after a single injection,
when effective, make BoNT-A a potential multi-purpose
drug for pain treatment in a variety of neurological and
non-neurological conditions. There are, however, several
open questions that warrant further studies.
PREEMPT data showed a mean reduction of approxi-
mately 2 headache days out of 4 weeks after BoNT-A in
comparison to placebo in chronic migraine patients [17].
Similarly, in many RCTs, self-rated pain reduction after
BoNT-A injection was generally no more than 2 points
on a visual analogue or numerical rating scale from 0 to
10 [26, 28, 29], which is insufficient to document a
satisfactory response in most patients. The association of
an ad hoc rehabilitative program was found to improve
the clinical efficacy of BoNT in cervical dystonia [43]. A
future area of focus for RCTs should be to explore the
potential role of BoNT injection therapy in combination
with systemic drugs and/or physical therapies.
Furthermore, BoNT was found to be effective on pain
through various routes of injection, including subcutane-
ous, intramuscular, and intraarticular ones. A small RCT
showed that BoNT-A profoundly prolonged (i.e.,
2 months on average) analgesia after bupivacaine sympa-
thetic blocks in patients with complex regional pain
syndrome, a devastating pain conditions with no estab-
lished treatment [44]. Comparison of different routes of
injection might offer new pieces of information for opti-
mizing the use of BoNT for the treatment of pain.
The most appropriate BoNT dosage is still unknown. In
MOH, onabotulinumtoxin-A 100 U was found to be inef-
fective on the headache days in a RCT [19], while an open
label prospective study that evaluated two doses of
onabotulinumtoxin-A (i.e., 155 U and 195 U) reported a
significant reduction of the number of headache and mi-
graine days for both doses, but with a superiority of the
higher dosage [45]. These data suggest that dose-finding
studies may represent another promising field of research.
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